AUTHOR=Jin Wei , Wang Xin , Wang Jie , Lin Lin 

TITLE=Case Report: Opportunities and Challenges of Immunotherapy in Heavily-Treated EGFR-Mutant Advanced Squamous Cell Lung Carcinoma After Progression on EGFR-TKIs and Chemotherapy

JOURNAL=Frontiers in Oncology

VOLUME=12

YEAR=2022

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.820408

DOI=10.3389/fonc.2022.820408

ISSN=2234-943X

ABSTRACT=<sec><title>Background</title><p>Epidermal growth factor receptor (EGFR) mutations have a low incidence in squamous cell lung cancer (SqCLC), and the clinical efficacy of EGFR tyrosine kinase inhibitors (TKIs) in <italic>EGFR</italic>-mutated SqCLC is far less than that in <italic>EGFR</italic>-mutated lung adenocarcinoma. The treatment strategy for patients with <italic>EGFR-</italic>mutated non-small cell lung cancer who are refractory to EGFR TKIs has become a current dilemma and challenge.</p></sec><sec><title>Case Presentation</title><p>A case of a 69-year-old male patient suffering from intermittent cough and hemoptysis was diagnosed with <italic>EGFR</italic>-mutated advanced SqCLC (stage cT2bN2M1). The patient was treated with camrelizumab alone after five courses of different systemic therapies and achieved a partial response, with an eminent progression-free survival of more than 24 months. Grade 1 to 2 reactive cutaneous capillary endothelial proliferation and mild pruritus were observed during the treatment. No other immune-related adverse events were observed.</p></sec><sec><title>Conclusion</title><p>Monotherapy of immune-checkpoint inhibitors may be considered as a later-line option for <italic>EGFR</italic>-mutated advanced SqCLC patients with PD-L1 expression.</p></sec>